Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

U.S. Supreme Court snubs Novartis appeal over arthritis drug Enbrel

Stock Markets May 17, 2021 12:51PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Novartis's logo is seen at the cell and gene therapy factory of the Swiss drugmaker in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Photo

By Andrew Chung

(Reuters) -The U.S. Supreme Court on Monday dashed Novartis AG's hopes of launching a generic version of Amgen Inc (NASDAQ:AMGN)'s multibillion-dollar rheumatoid arthritis drug Enbrel, declining to hear the company's challenge to two patents.

The justices turned away Novartis subsidiary Sandoz Inc's appeal of a lower court decision that upheld the validity of the patents.

Enbrel, also known as etanercept and used to treat adults with moderate to severe active rheumatoid arthritis, is Amgen's top-selling drug, accounting for nearly $5 billion of the company's $24.2 billion in product sales for 2020. Enbrel was launched in 1998 by Immunex Corp, which Amgen acquired in 2002.

At issue in the case is a principle of U.S. patent law that prevents inventors from extending the life of their existing patents by obtaining more than one patent on the same invention, or an obvious variation of it.

The case involves the active ingredient in Enbrel. After Sandoz sought to market Erelzi, a generic version of Enbrel, Immunex sued in 2016 for patent infringement.

Sandoz accused Immunex of impermissibly extending the life of its monopoly on Enbrel through a 2004 deal that effectively took over rival Roche's patent applications on similar research and amended them to cover Enbrel. The successful applications now protect Enbrel from competition until 2029.

In 2020, the Washington-based U.S. Court of Appeals for the Federal Circuit, which specializes in patent cases, rejected Sandoz's argument, saying that Immunex did not fully take over the Roche patents, which were therefore still valid.

"We are disappointed the Supreme Court decided not to review our case," Keren Haruvi, president of Sandoz US and head of its North America business, said in a statement.

Haruvi said the decision meant Erelzi, which is more affordable than Enbrel, "will not be available to U.S. patients with autoimmune and inflammatory diseases until 2029; nonetheless we remain committed to providing important treatment options for patients affected by these diseases."

U.S. Supreme Court snubs Novartis appeal over arthritis drug Enbrel
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Almir Shabanaj
Almir Shabanaj May 17, 2021 2:03PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
hell
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email